The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned

Mickael, Claudia; Lee, Michael H.; Graham, Brian B.

doi:10.1183/13993003.00796-2022

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Referring to the 6th WSPH (world symposium on pulmonary hypertension) guidelines in 2018 ( 7 ), the clinical classification of PH is: (1) pulmonary arterial hypertension, (2) PH caused by left heart disease; (3) PH caused by pulmonary disease and/or hypoxia; (4) PH caused by pulmonary artery obstructive disease; (5) unknown mechanism and/or multiple factor-induced PH. As with other cardiorespiratory disorders, patients with PH are at particularly high risk for clinical exacerbations associated with respiratory infections ( 8 , 9 ). Reciprocally, COVID-19 disease can also cause short-term or long-term adverse cardiovascular effects ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccination for children with pulmonary hypertension: efficacy, safety and reasons for opting against vaccination

Zhang,

Wang,

Zuo

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

ObjectiveTo determine the reasons why pulmonary hypertension (PH) children refused vaccination against COVID-19, evaluate the safety and efficacy of COVID-19 vaccine in PH children.Study designThis retrospective cohort study included congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) and bronchopulmonary dysplasia associated PH (BPD-PH) children who were divided into vaccinated group and non-vaccinated group. Univariate logistic regression analysis and multivariate logistic regression analysis were conducted to explore the reasons why PH children refused COVID-19 vaccine. Then, the prevalence, the number of symptoms, and the severity of COVID-19 disease were compared between the vaccinated and unvaccinated groups.ResultWe included 73 children and 61 children (83.6%) were unvaccinated. The main reasons for not being vaccinated were fear of worsening of existing diseases (31%). Age < 36 months (RR: 0.012; P < 0.001) and the presence of comorbidities (RR = 0.06; P = 0.023) were risk factors influencing willingness to vaccinate. The most common adverse events (AEs) were injection site pain (29.6%). COVID-19 vaccines are safe for PH children. The prevalence of COVID-19 disease decreased in PH children after vaccination (RR = 0.51; P = 0.009). 1 month after negative nucleic acid test or negative antigen test, PH children in the vaccinated group had fewer symptoms (P = 0.049).ConclusionsThe vaccination rate of COVID-19 vaccine is low in CHD-PAH and BPD-PH children while COVID-19 vaccines are safe. Vaccination can reduce the prevalence of COVID-19 disease and the number of symptoms 1 month after negative nucleic acid or antigen tests.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 vaccination for children with pulmonary hypertension: efficacy, safety and reasons for opting against vaccination

Zhang,

Wang,

Zuo

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned

Abstract: This editorial summarises the key findings of R. Badagliacca and co-workers regarding the changes in care and clinical outcomes of PAH patients during the initial COVID-19 pandemic in Italy https://bit.ly/3ytgIjk

Cited by 1 publication

References 27 publications

COVID-19 vaccination for children with pulmonary hypertension: efficacy, safety and reasons for opting against vaccination

COVID-19 vaccination for children with pulmonary hypertension: efficacy, safety and reasons for opting against vaccination

Contact Info

Product

Resources

About